Tag: IBD
AI Breakthrough Reveals How Two Proteins Could Protect Against Crohn’s
Cambridge researchers used AI to discover two proteins that work together to protect against Crohn’s disease, opening doors to personalized prevention and treatment approaches. This breakthrough could transform how we understand and manage IBD.
New Clinical Leader Brings Hope to GI Treatment Development
Palisade Bio has appointed Dr. Sharon Skare as VP of Clinical Operations to advance PALI-2108, a promising new GI therapy. Her 30+ years of experience could accelerate development of treatments for conditions with limited options.
Hidden Gut Engine Discovery Offers New Hope for Crohn’s Patients
Scientists have discovered a ‘hidden hydrogen engine’ in the gut that malfunctions in Crohn’s disease, potentially explaining digestive symptoms and opening doors to new diagnostic tools and treatments. This research offers hope for more personalized approaches to managing IBD.
Better IBD Treatments on the Horizon: What Growth Means for Patients
Market analysis shows unprecedented growth in IBD research and treatment development, with new biologics, personalized medicine, and digital health platforms on the horizon. Here’s what this expansion means for patients and families managing Crohn’s disease and ulcerative colitis.
New UC Research Tackles Bowel Urgency – The Symptom That Controls Your Life
New clinical trial data shows promising improvements in bowel urgency for ulcerative colitis patients, addressing the symptom that often controls daily life more than any other UC symptom.
New UC Treatment Shows Promise in Just 3 Days
New clinical trial data shows OMVOH, an FDA-approved UC treatment, can start improving symptoms in just three days while maintaining benefits for a full year. This rapid-acting approach could change how we experience UC treatment, offering hope for faster relief and long-term stability.
Could This Overlooked Gut Bacteria Be a Game-Changer for IBD?
New research identifies Ruminococcus torques, a gut bacterium that strengthens the intestinal barrier and may offer new hope for IBD management. This discovery could lead to more targeted, microbiome-based therapies for inflammatory bowel disease.
Tremfya Breakthrough: First At-Home UC Treatment Changes Everything
The European Commission has approved Tremfya as the first IL-23 inhibitor that can be self-administered at home for UC treatment. This groundbreaking approval could transform how patients manage moderate to severe ulcerative colitis by eliminating the need for hospital infusions.
The Mediterranean Diet for UC: Why This Matters for Your Journey
New research suggests the Mediterranean-Style Diet could help people with ulcerative colitis by focusing on anti-inflammatory foods and flexible eating patterns. This approach shifts from restriction to nourishment, offering hope for better symptom management.
Early Crohn’s Treatment: Game-Changer for Better Outcomes
New Cambridge research shows that treating Crohn’s disease aggressively from diagnosis leads to fewer flares, hospitalizations, and better quality of life over five years. This approach could transform IBD care by preventing intestinal damage rather than just managing symptoms.
